Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T20:11:31.592Z.
Calculation as of: 2026-10-06T20:11:31.592Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4936500bc1589ca9a686c77de910b68cd28581e4c5f82a550ef1f7d6df46dce9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Evogene Ltd.
Market Cap
$3.65M
EV/FCF Ratio
N/A
| NAME | MARKET CAP | EV/FCF RATIO |
|---|---|---|
| Evogene Ltd. (EVGN) | $3.65M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.67M | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.54M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.96M | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
